Gossamer Bio Stock Today
| GOSS Stock | USD 0.37 -0.02 -5.13% |
Performance
| Odds Of Distress
|
Gossamer Bio holds a current market valuation of $0.37 as of April 25, 2026, delivering a 5.13% decrease on the day. Forward-looking probability metrics estimate that Gossamer Bio carries 88% odds of experiencing financial distress. Over the last 90 trading days, it has delivered negative risk-adjusted returns. The performance scores are measured across the period from January 25, 2026 to April 25, 2026. Learn more.
IPO Date 8th of February 2019 | Asset Type Stock | Category Healthcare | Classification Health Care |
| 0.64 | VANI | Vivani Medical | PairCorr |
| 0.75 | DRMA | Dermata Therapeutics | PairCorr |
| 0.77 | VRAX | Virax Biolabs Group | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Stock Highlights
Gossamer Bio (GOSS) is listed on NASDAQ Exchange in USA. Gossamer Bio is part of the Biotechnology industry. The company conducts business in the Biotechnology sector. Market capitalization for Gossamer Bio is about 87.68 M, leaving the company classified as micro-cap across biotechnology companies. That size classification is easier to frame alongside enterprise value near 154.03 M, a workforce of about 161 people, and about 234.7 M shares outstanding. The company has 37.5 M shares sold short (2.74 days to cover). Gossamer Bio operates as a research-driven pharmaceutical developer where revenue is driven by drug pipeline progression, regulatory approvals, and patent-protected sales. Gossamer Bio currently holds $201.97 M in liabilities with Debt to Equity (D/E) ratio of 3.86, implying Gossamer Bio greatly relies on financing operations through borrowing. Gossamer Bio financial stability analysis Ownership Allocation The majority of Gossamer Bio's outstanding shares are owned by institutional investors. Institutional investors such as pension funds, mutual funds, and asset managers typically hold large positions as part of their investment mandates, managing money on behalf of clients or beneficiaries. As a result, they are subject to reporting requirements and oversight rules - such as 13F filings and position disclosure thresholds - that do not apply to individual retail investors. Check Gossamer Ownership DetailsHeadline Sentiment vs Price - Gossamer Bio
Average sentiment trends provide additional analytical context alongside traditional valuation metrics. Investor mood toward Gossamer Bio is presently assessed as neutral, according to analysis of 4 media-driven sentiment signals as of 2026-04-24.
Open Interest Against 2026-05-15 Gossamer Option Contracts
This chain summary highlights Gossamer Bio listed contracts for May 15, 2026. At this expiration, the listing mix is 9 calls and 9 puts (18 total). At a glance, metrics point to implied volatility near 2.34 and put/call open-interest ratio around 0.18. Strike-level open interest is available in the full chain. View more details.Open interest data for Gossamer Bio summarizes outstanding contracts across maturities. All values reflect reported contract activity.
Stock Notable Updates
| Legal Name | Gossamer Bio Inc |
| Co-Founder, CEO and President & Chairman | Faheem Hasnain |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare, (View all Sectors) |
Gossamer Bio (GOSS) recorded a Gross Profit Margin of 78.0%, an Operating Margin of -333.7%, and a Return On Capital Employed of -143.0%. Gossamer Bio demonstrates pressured financial positioning across liquidity and leverage indicators. The earnings picture reflects near-term margin compression relative to deployed assets.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.35 | 0.2814 |
|
| |||||
| Gross Profit Margin | 0.78 | 0.88 |
|
| |||||
| Total Current Liabilities | 38.1 M | 63.4 M |
|
| |||||
| Non Current Liabilities Total | 178.8 M | 231.6 M |
|
| |||||
| Total Assets | 288.4 M | 172.2 M |
|
| |||||
| Total Current Assets | 279.6 M | 167.6 M |
|
|
Current Assets
Gossamer Bio (GOSS) recorded $288.4 million in Total Assets, a Return On Tangible Assets of -104.0%, and a Debt To Assets of 227.0%. $13.2 million in Net Tangible Assets round out the key financial metrics view for Gossamer Bio.
Earnings per Share Projection vs Actual
Gossamer Bio's forward EPS estimates provide a structured view of expected profitability based on current analyst coverage. Gossamer Bio generates 48.47 Million in revenue, establishing the scale over which earnings per share are distributed.
Consensus EPS projections for Gossamer Bio's are based on current analyst assumptions and may be revised. Reported EPS TTM is historical and should not be read as a forecast.
Top Institutional Holders
Institutional Holdings in Gossamer Bio refers to the portion of shares owned by major financial entities. These holders often acquire large positions in Gossamer Bio and influence management through their ownership.| Instituion | Recorded On | Shares | |
| Palo Alto Investors, Llc | 2025-12-31 | 4.5 M | |
| Fmr Inc | 2025-12-31 | 4.2 M | |
| State Street Corp | 2025-09-30 | 3.9 M | |
| Perceptive Advisors Llc | 2025-09-30 | 3.8 M | |
| Millennium Management Llc | 2025-12-31 | 3.6 M | |
| Two Sigma Investments Llc | 2025-12-31 | 3.4 M |
Gossamer Bio Historical Income Statement
Gross Profit stood at 47.47 Million as of December 31, 2025. As of the week of April 25, Income Tax Expense is at approximately -83.6 K per recent reporting, even as demand moderates, Net Interest Income is reported at slightly above -9.5 M. View More FundamentalsGossamer Bio Against Markets
Stock Overview, Methodology & Data Sources
Gossamer Bio was incorporated in 2015 and is headquartered in San Diego, California. Gossamer Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Gossamer Bio employs 161 people. Headquarters are in 3115 Merryfield Row, San Diego, CA, United States, 92121. Latest reported figures include market cap 87.68 M, P/B 2.66, P/S 1.81. Gossamer Bio operates in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Fundamentals lead the analysis, with market-implied risk context alongside. The company is currently operating at a loss.
Methodology
Unless otherwise specified, financial data for Gossamer Bio is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Gossamer (USA Stocks:GOSS) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: This report references public filings and market reference sources and institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Certain datasets may update with delay depending on source availability. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Gossamer Bio may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board
Gossamer Bio Corporate Management
| Christian Waage | Executive Vice President of Technical Operations & Administration | Profile | |
| Caryn Peterson | Executive Vice President of Regulatory Affairs | Profile | |
| Matt Cravets | Senior Vice President of Biometrics | Profile | |
| Jeanine Anthony | Senior Vice President of Marketing | Profile | |
| Jeff Boerneke | General Counsel & Secretary | Profile | |
| Richard MD | Chief Medical Officer | Profile |